News Releases | Portage Biotech

Year

23 Nov '21

Portage Biotech Announces Financial Results and Provides Business Update for Second Quarter of 2022 Fiscal Year

Initiated PORT-2 Phase 1/2 IMP-MEL trial in patients with Melanoma & NSCLC Enrollment ongoing in Phase 1 PRECIOUS-01 study of PORT-3 for the treatment of NY-ESO-1 positive solid tumors WESTPORT, Conn. , Nov. 23, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the

22 Nov '21

Portage Biotech to Present at the Piper Sandler 33rd Annual Healthcare Conference

WESTPORT, Conn. , Nov. 22, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced

15 Nov '21

Portage Biotech Highlights Promising Efficacy and Survival Data Presented on Intensity Therapeutics’ INT230-6 (PORT-1) at November Scientific Conferences

Data presented at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting and Connective Tissue Oncology Society (CTOS) Annual Meeting suggest INT230-6 (PORT-1) offers a promising approach to treating metastatic disease, including advanced soft tissue sarcomas Data from Intensity

10 Nov '21

Portage Biotech Hosting Key Opinion Leader Webinar on How iNKT Agonists Could Improve Immuno-Oncology Treatment

Thursday, November 18th @ 10amET WESTPORT, Conn. , Nov. 10, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer

10 Sep '21

Portage Biotech Announces Participation in September 2021 Investor Conferences

WESTPORT, Conn. , Sept. 10, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company focused on the development of therapies and treatments targeting cancer treatment resistance, today announced that as part of its

30 Aug '21

Portage Biotech Announces Results for First Quarter of 2022 Fiscal Year

- $29 million raised during quarter with broad institutional support - Proceeds will accelerate advancement of clinical pipeline toward multiple data readouts over the next 18-24 months WESTPORT, Conn. , Aug. 30, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc.

12 Aug '21

Portage Biotech Issues Letter to Shareholders

WESTPORT, Conn. , Aug. 12, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. , (NASDAQ: PRTG) (“Portage” or the “Company”) a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today issued the following letter to shareholders: Dear

05 Aug '21

Portage Biotech Highlights First Patient Dosed in IMP-MEL Study of PORT-2 for the Treatment of Melanoma and Non-Small Cell Lung Cancer (NSCLC)

Novel iNKT agonist leads to a broad reprogramming of the innate and adaptive immune system to target cancer PORT-2 has the potential to re-sensitize checkpoint-resistant tumors to treatment with PD-1 antibodies WESTPORT, Conn. , Aug. 05, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc.

28 Jul '21

Portage Biotech Announces Results for Fiscal Year Ended March 31, 2021

- Transformative year included multiple corporate, clinical, and financial milestones, positioning Portage to accelerate development of first-in-class immuno-oncology assets - Additional clinical milestones and company progress anticipated throughout 2H 2021 and 2022 WESTPORT, Conn.

29 Jun '21

portage biotech added to russell 2000® index

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 19